ABBOTT INDIA LIMITED vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of ABBOTT INDIA LIMITED (ABBOTINDIA) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, ABBOTT INDIA LIMITED leads ABBOTINDIA vs TORNTPHARM on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

42.15
P/E ratio
74.52
11.45
P/B ratio
19.76
2.45%
Dividend yield
0.78%
₹665.64
EPS
₹63.92

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

33.41%
Return on equity
27.40%
46.00%
Return on capital
15.00%
26.00%
EBITDA margin
33.00%
22.06%
Net margin
15.29%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

9.01%
Revenue CAGR (3Y)
13.27%
17.82%
Profit CAGR (3Y)
19.75%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹59,614 Cr
Market cap
₹1.61L Cr
₹6,409 Cr
Revenue
₹13,980 Cr
₹1,414 Cr
Net profit
₹2,138 Cr
0.04
Debt / equity
1.79
ABBOTT INDIA LIMITED
  • + ["Company is almost debt free.", "Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%", "Company has been maintaining a healthy dividend payout of 69.6%"]
  • ["Stock is trading at 12.1 times its book value", "The company has delivered a poor sales growth of 9.96% over past five years."]
TORRENT PHARMACEUTICALS L
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 19.8 times its book value", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
ABBOTT INDIA LIMITED full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.